ECZEMA Mini Panel

Allergy

Report in 72Hrs

At Home

No Fasting Required

Details

Allergy panels for eczema triggers.

₹8,658₹12,369

30% OFF

ECZEMA Mini Panel - Comprehensive Medical Test Guide

Section 1: Why is it done?
- Test Purpose: The ECZEMA Mini Panel is a serological and immunological screening tool designed to identify allergic sensitivities and immune markers associated with atopic dermatitis (eczema) and related allergic conditions.
- Primary Indications: Patients presenting with chronic or recurrent eczema symptoms; suspected allergic contact dermatitis; evaluation of atopic individuals; assessment of allergen sensitivities contributing to dermatological manifestations; monitoring patients with known atopic conditions.
- Typical Components Tested: Total IgE levels; allergen-specific IgE antibodies; common environmental allergens (dust mites, mold, pollen, pet dander); food allergens (common triggers); Th1/Th2 cytokine profiles; inflammatory markers.
- Timing of Testing: Initial diagnostic evaluation in patients with suspected eczema; during acute flare-ups to assess triggering allergens; baseline assessment for treatment planning; routine monitoring in chronic eczema cases; following environmental or dietary interventions to gauge effectiveness.
Section 2: Normal Range
- Total IgE Levels: Normal range: 0-100 IU/mL (or < 150 IU/mL depending on laboratory). Values up to 150 IU/mL are generally considered normal.
- Allergen-Specific IgE: Negative/Not Detected: < 0.35 kUA/L (Kilounits of Allergen per Liter); Borderline: 0.35-0.69 kUA/L; Class 1 (Mild): 0.70-3.49 kUA/L; Class 2-6 (Moderate to Very High): ≥ 3.50 kUA/L and above.
- Interpretation Framework: Negative results indicate no significant allergic sensitization to tested allergens; Positive results (≥ 0.35 kUA/L) indicate allergic sensitization; Higher values correlate with greater likelihood of allergic symptoms; Normal total IgE with positive specific IgE suggests localized allergic response.
- Age-Related Considerations: Children may have slightly different normal ranges; Neonates typically have very low IgE levels; Values often increase with age and environmental exposure in atopic individuals.
Section 3: Interpretation
- Elevated Total IgE with Positive Specific IgE: Indicates strong atopic predisposition and multiple allergic sensitizations; Suggests increased likelihood of allergic eczema and other atopic manifestations; Correlates with higher disease severity and flare frequency.
- Normal Total IgE with Positive Specific IgE: Indicates selective allergic sensitization to specific allergens; Suggests localized allergic responses rather than systemic atopy; May indicate early-stage allergic disease or contact dermatitis.
- Elevated Total IgE with Negative Specific IgE: May indicate sensitization to allergens not included in the panel; Could suggest parasitic infections or other immune conditions; Warrants expanded allergen testing or alternative diagnostic modalities.
- Normal Total IgE with Negative Specific IgE: Suggests non-allergic eczema (irritant contact dermatitis or atopic dermatitis without allergic component); May indicate primary skin barrier dysfunction; Consider evaluation for genetic polymorphisms (FLG mutations) or non-IgE mediated responses.
- High Specific IgE Values (Class 5-6): Indicates strong sensitization and high probability of clinical reactivity; Strongly associated with symptomatic disease manifestations; Warrants aggressive allergen avoidance strategies and immunological interventions.
- Factors Affecting Interpretation: Recent antihistamine use may suppress responses; Active corticosteroid therapy can reduce IgE levels; Acute stress and hormonal cycles influence immune responses; Recent acute infections may transiently elevate IgE; Timing relative to allergen exposure affects specific IgE detection.
Section 4: Associated Organs
- Primary Organ System: Integumentary System (Skin) - primary target organ for eczema manifestations; Immune System - T-helper cells, B cells, and mast cells; Epithelial barrier components including epidermis and dermis.
- Associated Conditions: Allergic rhinitis (hay fever); Allergic asthma; Food allergies; Anaphylaxis risk; Allergic conjunctivitis; Urticaria (hives); Angioedema; Atopic syndrome (atopic triad).
- Diseases Aided in Diagnosis: Atopic Dermatitis (AD); Contact Dermatitis (allergic); Allergic Rhinitis; Asthma; IgE-mediated food allergies; Occupational dermatitis; Systemic allergic conditions; Urticaria and related conditions.
- Potential Complications of Abnormal Results: Severe uncontrolled eczema leading to infection; Secondary bacterial infections (Staphylococcus aureus); Systemic allergic reactions if allergen exposures occur; Progression to respiratory involvement (asthma); Sleep disruption and decreased quality of life; Psychological impact (anxiety, depression); Impaired skin barrier function leading to infections.
- Systemic Involvement: Elevated IgE can indicate systemic immune dysfunction; Lymphoid tissue (lymph nodes, thymus) involved in antibody production; GI tract may be secondarily affected (food allergies); Respiratory system at risk for atopic march progression.
Section 5: Follow-up Tests
- Confirmatory and Complementary Tests: Skin Prick Testing (SPT) for confirming IgE-mediated sensitization; Patch Testing for contact dermatitis evaluation; Intradermal testing for environmental allergens; Component-resolved diagnostics (CRD) for specific allergen proteins.
- Expanded Allergen Panels: Extended Environmental Allergen Panel; Comprehensive Food Allergen Panel; Occupational/Workplace Allergen Panel; Regional specific allergen panels; Mold and fungal allergen testing.
- Immunological Assessment: T-cell cytokine profiling (IFN-γ, IL-4, IL-5, IL-13); T regulatory cell (Treg) assessment; Eosinophil count; Lymphocyte subset analysis; Immunoglobulin subclass testing (IgG, IgA, IgM).
- Genetic and Molecular Testing: Filaggrin (FLG) gene mutation analysis; TSLP polymorphisms; IL-4 receptor variants; Assessment for genetic predisposition to atopy.
- Microbiological Testing: Skin bacterial culture (for secondary infections); Fungal culture/testing (candida, dermatophytes); Microbiome analysis for dysbiosis assessment.
- General Health Monitoring: Complete blood count (CBC) with differential; Comprehensive metabolic panel; Thyroid function tests; Vitamin D levels; Iron studies.
- Recommended Monitoring Frequency: Baseline comprehensive testing upon initial diagnosis; Repeat testing annually for ongoing management; More frequent testing (3-6 months) during acute flares or treatment changes; Post-intervention testing (3-6 months) to assess therapeutic response; Periodic reassessment when clinical status changes.
Section 6: Fasting Required?
- Fasting Requirement: NO - Fasting is NOT required for the ECZEMA Mini Panel test.
- Rationale: IgE and allergen-specific antibody levels are not significantly affected by food intake or metabolic state; Measurements are based on immune response rather than metabolic parameters.
- Specimen Collection: Blood draw can be performed at any time of day; No need to schedule appointments specifically for fasting windows; Patient comfort and convenience are primary considerations.
- Important Medications to Avoid/Considerations: First-generation antihistamines (H1 blockers) - Discontinue 3-5 days before testing if skin testing is planned; H2 blockers (for GI issues) - Discontinue 24 hours before if skin testing planned; Tricyclic antidepressants - May have antihistamine properties; Discontinue 3-5 days before skin testing if applicable; Corticosteroids (topical/systemic) - Can suppress immune response; Note duration of use; Omalizumab (anti-IgE therapy) - Can significantly reduce detectable IgE levels.
- Patient Preparation Instructions: Eat and drink normally before the appointment; Wear loose-fitting clothing for easy arm access; Avoid scratching or irritating skin at collection site; Inform phlebotomist of any active dermatitis or skin conditions; Report current medications and supplements; Stay hydrated; Avoid strenuous exercise immediately before blood draw.
- Optimal Testing Conditions: Test during periods of skin remission if possible (not during acute flares); Wait at least 2 weeks after acute eczema exacerbation; Schedule when patient is not acutely ill; Avoid testing immediately after recent infections or vaccinations (wait 4 weeks); Early morning collection is preferred when possible; Separate from other blood work by only one needle stick.
- Special Populations: Pregnant patients - Test can proceed normally; Elderly patients - Standard preparation applies; Pediatric patients - Age-appropriate arm positioning and comfort measures; Immunocompromised patients - Timing should be discussed with healthcare provider.

How our test process works!